CADL — Candel Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $260.14m
- $169.99m
- 40
- 18
- 23
- 16
Annual income statement for Candel Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.125 | 0.125 | 0.125 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 13.9 | 25.9 | 34.8 | 38.4 | 33.4 |
| Operating Profit | -13.8 | -25.7 | -34.7 | -38.4 | -33.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -17.7 | -36.1 | -18.8 | -37.9 | -55.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -17.7 | -36.1 | -18.8 | -37.9 | -55.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -17.7 | -36.1 | -18.8 | -37.9 | -55.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -17.7 | -36.1 | -18.8 | -37.9 | -55.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.636 | -1.88 | -0.652 | -1.3 | -1.74 |